TARGIT - IORT
Intrabeam TARGIT IORT is targeted intraoperative radiotherapy treatment for breast cancer. Conceived in the UK more than 20 years ago, thoroughly tested in clinical trials, TARGIT IORT treatment is widely used to treat breast cancer patients across the world.
“The most important benefit of TARGIT for a woman with breast cancer is that it allows her to complete her entire local treatment [lumpectomy and radiation therapy] at the time of her operation, with lower toxicity.” Lancet 2014;383:603-613
Please visit the dedicated website for TARGIT-IORT
Special relevance of TARGIT-IORT during the COVID-19 pandemic
TARGIT-IORT is given as a single dose during the cancer operation - so in most patients no visits to the radiotherapy department are required. This is especially relevant during the COVID-19 pandemic. When the radiotherapy is completed during the cancer operation, under the same anaesthetic, it greatly reduces the need for repeated post-operative visits to the hospital for postoperative external beam radiotherapy which are necessary for regimens such as IMPORT-Low or Fast-Forward which irradiates the whole breast.
This is why it has been included in several national and international guidelines for treatment of breast cancer during the COVID-19 pandemic caused by the widespread infection with the SARS-CoV-2 virus
During the COVID-19 pandemic, new guidelines for treatment of beast cancer and radiotherapy have recommend using TARGIT-IORT because it would save patients the daily travel (and viral exposure) to radiotherapy departments:
Global radiation oncology's targeted preparedness for COVID-19
“where the technology is available the use of IORT may obviate the need for any further outpatient treatment and should be considered an option ..”
British Association of Cancer Surgery (BASO~ACS) https://baso.org.uk/media/98159/covid_19_and_breast_cancer_march_2020.pdf
German University Hospitals
Italian Association of Radiotherapy and Clinical Oncology
China is increasing its use of TARGIT-IORT #breastcancer by equipping more centres with the TARGIT-IORT equipment
Click here to see the national and international guidelines recommending TARGIT-IORT for breast cancer
Information about Intrabeam TARGIT IORT
Why is radiotherapy used for breast cancer?
Breast cancer is frequently treated by surgically removing the cancerous lump with a margin of surrounding normal tissue. Radiotherapy to the remaining breast after such a lumpectomy reduces the risk of cancer coming back in the breast. Traditional external beam radiotherapy (EBRT) is given to the whole breast a few weeks after surgical removal of the cancer. As it is not focused, it needs to be given in daily small doses over three to six weeks.
What is Intraoperative radiotherapy | Intrabeam | TARGIT | IORT for breast cancer?
What is the surgical procedure of giving TARGIT IORT?
TARGIT IORT is given using the Intrabeam device. It is given during your surgery, while you remain asleep, under general anaesthetic. It adds about 30 minutes to the operation.
Has TARGIT IORT been clinically tested for breast cancer?
What will it involve?
Who can and cannot have TARGIT IORT?
Women who are 45 or older with invasive ductal type cancer suitable for breast conservation (tumour size up to 3.5cm) are eligible to receive TARGIT IORT instead of EBRT. Other women who have a higher risk cancer can receive TARGIT as a tumour-bed boost in addition to EBRT within the TARGIT-B trial. Women who need a mastectomy are not suitable.
Key Benefits of Intrabeam TARGIT IORT
Key Concerns about Intrabeam TARGIT IORT
Intrabeam TARGIT IORT for breast cancer is clinically effective - confirmed in the TARGIT-A international clinical trial
First publication of the main results (2010)
Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial.
5-year results and first analysis of survival (2014)
Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial.
Full 226 page report of the TARGIT-A trial of Intrabeam TARGIT IORT for HTA, NIHR, Department of Health, UK (2016)
An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial).
Long term outcomes of the TARGIT-A trial (2020)
Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial
BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m2836 (Published 19 August 2020)
Recent peer reviewed publications are below: more are available here
The TARGIT-A trial of intraoperative radiotherapy for breast cancer
What is gambling?
What is problem gambling?
Problem gambling is an urge to continuously gamble despite harmful negative consequences or a desire to stop. Problem gambling is often explained by whether harm is experienced by the gambler or others, rather than by the gambler’s behaviour. Severe problem gambling may be diagnosed as clinical pathological gambling if the gambler meets certain criteria. Pathological gambling is a common disorder that is associated with both social and family costs.
Can we help?
What is the player's charter?
Players Charter is a document which was written in order to set out guidelines for both the authority personnel as well as to consumers related to gambling and standards of service.
How many remote gaming companies are licensed in Malta?
Over 250 remote gaming companies call this island paradise home and the remote gaming sector is responsible for over 12% of the country’s GDP.
What is Responsible Gaming?
They may gamble for pleasure and entertainment but are aware of their likelihood of losing and understand the associated risks,
They exercise control over their gambling activity, and
Responsible gambling occurs in balance with other activities in their lives and is not causing problems or harm for themselves or others.
Shared responsibility for generating awareness of the risks associated with gambling,
Creating and promoting environments that prevent or minimise problem gambling, and being responsive to community concerns around gambling.